Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type.

Trial Profile

Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Tarenflurbil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 28 Apr 2012 Planned number of patients changed from 1000 to 1661 as reported by European Clinical Trials Database.
    • 01 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top